Petros Pharmaceuticals PTPI
€ 0.24
0.12%
Quartalsbericht 2024-Q3
hinzugefügt 13.11.2024
Petros Pharmaceuticals Bilanz 2011-2024 | PTPI
Bilanz Jährlich Petros Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nettoverschuldung |
-13 M | -9.02 M | -23.3 M | -9.96 M | 11.6 M | - | - | - | - | - | - | - | - |
Langfristige Schulden |
138 K | 263 K | 405 K | - | 7.06 M | - | - | - | - | - | - | - | - |
Langfristiger Schuldenstrom |
125 K | 142 K | 126 K | - | - | - | - | - | - | - | - | - | - |
Langfristige Verbindlichkeiten |
- | - | - | 601 K | 9.24 M | - | - | - | - | - | - | - | - |
Kurzfristige Verbindlichkeiten |
10.8 M | 7.07 M | 31 M | - | - | - | - | - | - | - | - | - | - |
Gesamtverbindlichkeiten |
21.3 M | 15.7 M | 31.8 M | 52.4 M | 50.3 M | - | - | - | - | - | - | - | - |
Aufgeschobenes Einkommen |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gewinnrücklagen |
-98.9 M | -90.7 M | -70.7 M | - | -41.1 M | - | - | - | - | - | - | - | - |
Vermögenswerte |
33.8 M | 32.4 M | 67.4 M | 69.9 M | 58.4 M | - | - | - | - | - | - | - | - |
Zahlungsmittel |
13.3 M | 9.43 M | 23.8 M | 17.1 M | - | - | - | - | - | - | - | - | - |
Buchwert |
12.5 M | 16.7 M | 35.5 M | 17.5 M | 8.02 M | - | - | - | - | - | - | - | - |
Gesamtes Eigenkapital |
12.1 M | 16.7 M | 35.5 M | 17.5 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Bilanz Vierteljährlich Petros Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Langfristige Schulden |
- | - | - | - | 151 K | 183 K | 224 K | 263 K | 300 K | 336 K | 371 K | 405 K | 438 K | 470 K | 501 K | 531 K | 531 K | - | 531 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Langfristige Verbindlichkeiten |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gesamtverbindlichkeiten |
17.6 M | 16 M | 19.6 M | 21.3 M | 31.9 M | 15.8 M | 15.1 M | 15.7 M | 17 M | 16.8 M | 20.1 M | 31.8 M | 34.2 M | 37.2 M | 45.2 M | 52.4 M | 52.4 M | - | 52.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Aufgeschobenes Einkommen |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gewinnrücklagen |
-104 M | -102 M | -101 M | -98.9 M | -99.2 M | -94.7 M | -92.1 M | -90.7 M | -86.5 M | -72.7 M | -70.9 M | -70.7 M | -62.5 M | -60.8 M | -58.7 M | -61.7 M | -61.7 M | - | -61.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Vermögenswerte |
20.7 M | 25.2 M | 30.3 M | 33.8 M | 38.9 M | 28.7 M | 30.6 M | 32.4 M | 37.7 M | 51 M | 55.9 M | 67.4 M | 52 M | 56.7 M | 66.2 M | 69.9 M | 69.9 M | - | 69.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Zahlungsmittel |
3.9 M | 7.5 M | 11.1 M | 13.3 M | 18 M | 7.38 M | 8.32 M | 9.43 M | 11.2 M | 13.3 M | 17.7 M | 23.8 M | 8.14 M | 11 M | 14.6 M | 17.1 M | 17.1 M | 832 K | 17.1 M | 2.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Buchwert |
3.12 M | 9.19 M | 10.7 M | 12.5 M | 7.06 M | 12.9 M | 15.4 M | 16.7 M | 20.7 M | 34.2 M | 35.7 M | 35.5 M | 17.8 M | 19.5 M | 20.9 M | 17.5 M | 17.5 M | - | 17.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gesamtes Eigenkapital |
3.12 M | 8.07 M | 9.79 M | 12.1 M | 6.93 M | 12.9 M | 15.4 M | 16.7 M | 20.7 M | 34.2 M | 35.7 M | 35.5 M | 17.8 M | 19.5 M | 20.9 M | 17.5 M | 17.5 M | -3.83 M | 17.5 M | 8.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung